Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan

Nagano, Mitsuhiro; Kamei, Kazumasa; Matsuda, Hiroyuki; Takahashi, Chihiro; Yang, Jingyan; Wada, Koji; Yonemoto, Naohiro

doi:10.1080/14760584.2024.2323133

Cited by 4 publications

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis

Nagano,

Tanabe,

Kamei

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Japan will be transitioning from the free-of-charge COVID-19 vaccination program to annual periodic vaccination under a national immunization program for old adults and high-risk patients from 2024 fall/winter season. The policy transition including out-of-pocket payment requirement may discourage vaccination, leading to a lower vaccination rate. This study aimed to estimate the impact of varying vaccination rates with BNT162b2 COVID-19 mRNA vaccine on economics and public health in an illustrative prefecture which administers and promotes the periodic vaccination program, using budget impact analysis. Methods A combined cohort Markov decision tree model estimated the public health outcomes of COVID-19-related symptomatic cases, hospitalizations and deaths; and the economic outcomes including vaccine-related cost, non-vaccine-related medical cost, and productivity loss from the societal perspective. The base case examined the impact on the outcomes when vaccination coverage changed from the reference value of 50% to upper and lower values, respectively. Scenario analyses were performed based on multiple scenarios. Results Increase in the vaccination rate demonstrated improvement in all public health outcomes. At 50% vaccination, the vaccine-related cost for 3 years in a prefecture was estimated at JPY 7.58 billion (USD 57.67 million), the non-vaccine-related medical cost at JPY 79.22 billion (USD 602.48 million), the productivity loss at JPY 253.11 billion (USD 1.92 billion), and the total cost at JPY 339.92 billion (USD 2.59 billion). When the vaccination rate increased to 90%, the total cost decreased by JPY 4.88 billion (USD 37.11 million) (1.4%). When the vaccination rate decreased to 10%, the total cost increased by JPY 5.73 billion (USD 43.58 million) (1.7%). Results were consistent across almost all scenario analyses. Conclusions Maintaining a high vaccination rate with BNT162b2 is important from both public health and economic perspectives in Japan. The findings highlight to local governments the importance of continued effort to promote vaccination. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-024-01032-y.

show abstract

Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis

Nagano,

Tanabe,

Kamei

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

show abstract

Impact of High Covid-19 Vaccination Rate in an Aging Population: Estimating Averted Hospitalizations and Deaths in the Basque Country, Spain Using Counterfactual Modeling

Estadilla,

Mar,

Ibarrondo

et al. 2024

J Epidemiol Glob Health

View full text Add to dashboard Cite

COVID-19 vaccines have demonstrated significant efficacy in reducing severe symptoms and fatalities, although their effectiveness in preventing transmission varies depending on the population’s age profile and the dominant variant. This study evaluates the impact of the COVID-19 vaccination campaign in the Basque Country region of Spain, which has the fourth highest proportion of elderly individuals worldwide. Using epidemiological data on hospitalizations, ICU admissions, fatalities, and vaccination coverage, we calibrated four versions of an ordinary differential equations model with varying assumptions on the age structure and transmission function. Counterfactual no-vaccine scenarios were simulated by setting the vaccination rate to zero while all other parameters were held constant. The initial vaccination rollout is estimated to have prevented 46,000 to 75,000 hospitalizations, 6,000 to 11,000 ICU admissions, and 15,000 to 24,000 deaths, reducing these outcomes by 73–86%. The most significant impact occurred during the third quarter of 2021, coinciding with the Delta variant’s dominance and a vaccination rate exceeding 60%. Sensitivity analysis revealed that vaccination coverage had a more substantial effect on averted outcomes than vaccine efficacy. Overall, the vaccination campaign in the Basque Country significantly reduced severe COVID-19 outcomes, aligning with global estimates and demonstrating robustness across different modeling approaches. Supplementary Information The online version contains supplementary material available at 10.1007/s44197-024-00286-6.

show abstract

Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes

Nagano,

Hyokai,

Togo

et al. 2024

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan

Cited by 4 publications

References 28 publications

Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis

Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis

Impact of High Covid-19 Vaccination Rate in an Aging Population: Estimating Averted Hospitalizations and Deaths in the Basque Country, Spain Using Counterfactual Modeling

Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes

Contact Info

Product

Resources

About